Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. — Stella

Recruiting

Back to Hidradenitis Suppurativa trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Dermatology Hospital affiliated to Shandong First Medical University, Jinan, Shandong

Key details

Phase

Early testing / Safety & dosing

Sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.

Collaborators

Dermatology Hospital affiliated to Shandong First Medical University

Enrollment target

~15 participants

Started

March 2025

Primary completion

January 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov